Tempus AI (TEM) is trading down at $54.04 (-9.34%) on NASDAQ, as of the latest quote. It is a Russell 1000 constituent in the Health Care sector.
Current price targets from 3 firms average $81.7, median $75, ranging from $70 to $100 — the average is 51% above the current $54. Each is tracked to its date and scored the same way a member's call is.
3 targets, newest first. Open a row for its source and scoring.
Entry price $77.8, the close nearest Nov 3, 2026, when the target was reported; the target is +29% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.
Scoring Open: judged on the close on Nov 3, 2027.
BTIG raised its price target on Tempus AI Inc (NASDAQ:TEM) shares to $100 from $80
Entry price $77.8, the close nearest Nov 3, 2026, when the target was reported; the target is -10% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.
Scoring Open: judged on the close on Nov 3, 2027.
Jefferies upgraded Tempus AI Inc (NASDAQ:TEM) from Underperform to Hold and raised its price target to $70.00 from $35.00.
Entry price $78, the close nearest Sep 21, 2026, when the target was reported; the target is -4% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Sep 2027.
Scoring Open: judged on the close on Sep 21, 2027.
with a Neutral rating and a price target of $75.00 on Monday.
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
| FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $320.7M | $531.8M | $693.4M | $1.27B |
| Growth (year over year) | — | +65.8% | +30.4% | +83.4% |
| Operating income | −$265.4M | −$196.1M | −$691.1M | −$252.9M |
| Operating margin | −82.8% | −36.9% | −99.7% | −19.9% |
| Net income | −$289.8M | −$214.1M | −$705.8M | −$245.0M |
| Net margin | −90.4% | −40.3% | −101.8% | −19.3% |
| EPS (diluted) | −$5.30 | −$4.20 | −$6.23 | −$1.41 |
| Balance sheet | ||||
| Cash and equivalents | $302.9M | $165.8M | $341.0M | $604.8M |
| Total assets | — | $564.1M | $926.1M | $2.27B |
| Total liabilities | — | $840.7M | $869.8M | $1.78B |
| Shareholders' equity | −$1.13B | −$1.38B | $56.3M | $491.3M |
| Cash flow | ||||
| Operating cash flow | −$168.2M | −$214.3M | −$189.0M | −$218.1M |
| Capital expenditure | $18.4M | $34.6M | $22.1M | $21.0M |
| Free cash flow | −$186.6M | −$248.9M | −$211.2M | −$239.1M |
| Dividends paid | $5.63M | $5.63M | $5.63M | $0 |
| Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | Q3 FY26Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $200.7M | $255.7M | $314.6M | $334.2M | $367.2M | $348.1M | $382.5M | $411.5M |
| Growth (year over year) | +35.8% | +75.4% | +89.6% | +84.7% | +83.0% | +36.1% | +21.6% | +23.1% |
| Operating income | −$50.7M | −$68.7M | −$61.8M | −$61.0M | −$61.4M | −$84.7M | −$75.9M | −$56.9M |
| Operating margin | −25.3% | −26.9% | −19.6% | −18.3% | −16.7% | −24.3% | −19.8% | −13.8% |
| Net income | −$13.0M | −$68.0M | −$42.8M | −$80.0M | −$54.2M | −$125.9M | $5.64M | −$14.9M |
| Net margin | −6.5% | −26.6% | −13.6% | −23.9% | −14.8% | −36.2% | 1.5% | −3.6% |
| EPS (diluted) | $0.81 | −$0.40 | −$0.25 | −$0.46 | −$0.31 | −$0.71 | $0.03 | −$0.08 |
| Balance sheet | ||||||||
| Cash and equivalents | $341.0M | $151.6M | $186.3M | $655.9M | $604.8M | $521.2M | $599.6M | $590.5M |
| Total assets | $926.1M | $1.54B | $1.63B | $2.28B | $2.27B | $2.14B | $2.37B | $2.45B |
| Total liabilities | $869.8M | $1.22B | $1.32B | $1.77B | $1.78B | $1.72B | $1.92B | $1.95B |
| Shareholders' equity | $56.3M | $326.2M | $309.6M | $507.8M | $491.3M | $416.4M | $444.9M | $500.4M |
| Cash flow | ||||||||
| Operating cash flow | −$39.3M | −$105.6M | $44.2M | −$119.8M | −$36.8M | −$73.3M | −$7.53M | $9.22M |
| Capital expenditure | $7.96M | $2.07M | $7.51M | $6.71M | $4.75M | $8.20M | $6.13M | $9.34M |
| Free cash flow | −$47.2M | −$107.7M | $36.6M | −$126.5M | −$41.5M | −$81.5M | −$13.7M | −$122.0K |
| Dividends paid | $0 | — | — | $0 | $0 | — | — | — |
From Tempus AI's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
Read at The Motley Fool ↗ Link to this story
Also mentions Grail Inc
Read at Investing.com ↗ Link to this story
Read at Investing.com ↗ Link to this story
Read at CNBC ↗ Link to this story
Also mentions Oracle Corporation, SpaceX
Read at Investing.com ↗ Link to this story
Also mentions Lilly (Eli), Coinbase
Read at Yahoo Finance ↗ Link to this story
Also mentions Goldman Sachs
Tempus AI, Inc. is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM."